Liver and biliary problems in cystic fibrosis

Seminars in Liver Disease

Volumn 18, Issue 3, 1998, Pages 227-235

  Colombo, Carla ^a   Battezzati, Pier Maria ^b   Strazzabosco, Mario ^b   Podda, Mauro ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

CFTR (cystic fibrosis transmembrane regulator); Cholangiocytes; Cystic fibrosis; Liver disease; Ursodeoxycholic acid

Indexed keywords

BICARBONATE; BILE ACID; CHLORIDE CHANNEL; CHLORIDE ION; ESSENTIAL FATTY ACID; TRANSMEMBRANE CONDUCTANCE REGULATOR; URSODEOXYCHOLIC ACID;

ALKALINIZATION; BILE SECRETION; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; HEPATOBILIARY DISEASE; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0031712802     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007159     Document Type: Review

References (84)

1. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993;105:1857-1864
2. Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child 1995;72:281-284
3. Colombo C, Battezzati PM, Podda M Hepatobiliary disease in cystic fibrosis. Semin Liver Dis 1994;14:259-269
4. Fitz JG, Basavappa S, McGill J, Melhus O, Cohn JA. Regulation of membrane chloride currents in rat bile duct epithelial cells J Clin Invest 1993;91:319-328
5. Strazzabosco M, Boyer JL. Ion transporters that regulate intracellular pH and secretion in bile duct epithelial cells. In: Sirica AE. Longnecker DS (eds): Pathology of intrahepatic biliary and pancreatic duct cells. New York, Marcel Dekker Inc., 1996, pp 113-118
6. Strazzabosco M, Zsembery A, Fabris L. Electrolyte transport in bile ductular epithelial cells. J Hepatol 1996;24 (suppl 1):78-87
7. Strazzabosco M, Mennone A, Boyer JL. Intracellular pHi regulation in isolated rat bile duct epithelial cells. J Clin Invest 1991; 87:1503-1512
8. Alvaro A, Cho WK, Mennone A, Boyer JL. Effect of secretin on pHi regulation in isolated rat bile duct epithelial cells. J Clin Invest 1993;92:1314-1325
9. Roberts SK, Kuntz SM, Gores GJ, LaRusso NF. Regulation of bicarbonate-dependent ductular bile secretion assessed by luminal micropuncture of isolated rodent intrahepatic bile ducts. Proc Natl Acad Sci USA 1995;92:6527-6531
10. - cotransport participates in stimulated fluid secretion in isolated polarized bile duct units from rat liver [Abstract]. Hepatology 1996;24:149A
11. McGill JM, Basavappa S, and Fitz JG. Characterization of high conductance anion channels in rat bile duct epithelial cells. Am J Physiol 1992;262:G703-G710
12. McGill JM, Gettys TW, Basavappa S and Fitz JG. GTP-binding proteins regulate high conductance anion channels in rat bile duct epithelial cells. J Membrane Biol 1993;133:253-261
13. - channels in bile duct epithelial cells through a cAMP-dependent mechanism. Am J Physiol 1994;266:G731-G736
14. McGill JM, Basavappa S, Shimohura GH, Middleton JP, and Fitz JG. ATP activates ion permeabilities in biliary epithelial cells. Gastroenterology 1994;107:236-243
15. - secretion. Am J Physiol 1997;272:G872-G878
16. Reisin IL, Prat AG, Abraham EH, Amara JF, Gregory RJ, Ausiello DA, Cantiello HF. The cystic fibrosis transmenbrane conductance regulator is a dual ATP and chloride channel. J Biol Chem 1994;32:20584-20591
17. Schwiebert EM, Egan ME, Hwang T-H, et al. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995;81:1063-1073
18. Argent BE and Gray MA. Regulation and formation of fluid and electrolyte secretions by pancreatic duct epithelium. In: Sirica AE, Longnecker DS (eds): Pathology of intrahepatic biliary and pancreatic duct cells. New York, Marcel Dekker Inc, 1996, pp 349-377
19. Marino CR. CFTR and the pathophysiology of pancreatic disease in cystic fibrosis. In: Sinca AE, Longnecker DS (eds): Pathology of intrahepatic biliary and pancreatic duct cells. NewYork, Marcel Dekker Inc., 1996, pp 379-407
20. Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996;4:65-73
21. Kerem E, Corey M, Kerem B, et al. The relation between genotype and phenotype in cystic fibrosis. Analysis of the most common mutation (DF 508). N Engl J Med 1990;323:1517-1522
22. Ferrari M, Colombo C, Sebastio G, Castiglione O, Quattrucci S, Dalla Piccola B, Leoni G, Zanda M, Romano L, Devoto M. Cystic fibrosis patients with liver disease are not genetically distinct [Letter]. Am J Hum Gen 1991;48:815-816
23. Duthie A, Doherty DG, Williams C, et al. Genotype analysis for DF 508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without liver disease. Hepatology 1992;15:660-664
24. Kovesi T, Corey M, Tsui L-C, Levison H, Durie P. The association between liver disease and mutations of the cystic fibrosis gene [Abstract]. Pediatr Pulmonol 1992#ppl 8:244
25. Colombo C, Apostolo MG, Ferrari M, et al Analysis of risk factors for the development of liver disease in cystic fibrosis. J Pediatr 1994;124:393-399
26. Mack DR, Traystman MD, Colombo JL, et al. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr 1995;127:881-887
27. Peters RHPC, French PJ, Van Doorninck JH, et al. CFTR expression and mucin secretion in cultured mouse gallbladder epithelial cells. Am J Physiol 1996;271:G1074-G1083
28. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: Possible relation to focal biliary cirrhosis. J Pediatr 1975;86:683-689
29. Lindblad A, Hultcrantz R, Strandvik B. Bile duct destruction and collagen deposition: A prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992;16:372-381
30. Adams DH. Biliary epithelial cells: Innocent victims or active participants in immune-mediated liver disease? J Lab Clin Med 1996;128:528-530
31. Besanon F, Przewlocki G, Bar I, Hongre A-S, Escande D, Edelman A. Interferon-γ downregulates CFTR gene expression in epithelial cells. Am J Physiol 1994;267:C1398-C1404
32. Chari RS, Schutz SM, Haebig JE, et al. Adenosine nucleotides in bile. Am J Physiol 1996;270:G246-G252
33. Elsing C, Kassner A, Stremmel W. Sodium: Hydrogen antiporter activation by extracellular adenosine triphosphate in biliary epithelial cells. Gastroenterology 1996;111:1321-1332
34. - transport through CFTR-mediated ATP release in bile duct cells [Abstract]. Hepatology 1996;24:255A
35. Schlosser SF, Burgstahler AD, Nathanson MH. Isolated rat hepatocytes can signal to other hepatocytes and bile duct cells by release of nucleotides. Proc Natl Acad Sci USA 1996;93:9948-9953
36. Williams SGJ, Westaby D, Tanner MS, Mowat AP. Liver and biliary problems in cystic fibrosis. Br Med Bull 1992;48:877-892
37. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portman BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13: 129-133
38. Gaskin KJ, Waters DLM, Howman-Giles R, et al. Liver disease and common bile-duct stenosis in cystic fibrosis. N Engl J Med 1988;318:340-346
39. Nagel RA, Javaid A, Meire HB, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989;2: 1422-1425
40. Weber AM, Lenaerts C, Smith L, Roy CC. Screening and diagnosis of cystic fibrosis-related liver disease. Pediatr Pulmonol 1989#ppl 4:40-41
41. O'Brien S, Keogan M, Casey M, et al. Biliary complications of cystic fibrosis. Gut 1992;33:387-391
42. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991;66:698-701
43. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis. Therapeutic implications and long-term follow-up. Arch Dis Child 1993;68:653-657
44. FitzSimmons SC. Cystic Fibrosis Foundation. Patient Registry 1994 Annual Data Report. Bethesda, Maryland, 1995
45. Colombo C, Battezzati PM, Comi S, Melzi ML, Giunta A. Natural history of cirrhosis in cystic fibrosis. Israel J Med Sci 1996; 32:S79-S80
46. Maurage C, Lenaerts C, Weber AM, Brochu P, Yousef I, Roy CC Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: An autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;9:17-20
47. Lindblad A, Hjelte L, Strandvik B Incidence of liver disease in patients with cystic fibrosis and meconium ileus [Letter]. J Pediatr 1995;125:155-156
48. Tanner MS. Liver and biliary problems in cystic fibrosis J R Soc Med 1992;85 (suppl 19):20-24
49. Westaby D. Liver and biliary disease in cystic fibrosis. In: Hodson ME, Gadders DM (eds): Cystic fibrosis. London, Chapman & Hall, 1995, pp 281-293
50. Bilton D, Fox R, Webb AK, et al. Pathology of common bile duct stenosis in cystic fibrosis. Gut 1990;31:236-238
51. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992;15:677-684
52. Semih Dogan A, Conway JJ, Lloyd-Still JD. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease. J Nucl Med 1994;35:432-435
53. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatobiliary scintigraphy in cystic fibrosis. Hepatology 1996;23:281-287
54. Williams SGJ, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995;22:513-521
55. st European Cystic Fibrosis Conference (EWGCF). Davos. Switzerland, 1997, pp 55-58
56. Soto JA, Barish MA, Yucel EK, Siegenberg D, Ferrucci JT, Chuttani R. Magnetic resonance cholangiography: Comparison with endoscopic retrograde cholangio-pancreatography. Gastroenterology 1996;110:589-597
57. st European Cystic Fibrosis Conference (EWGCF), Davos, Switzerland, 1997, pp 48-50
58. Durieu I, Pellet O, Gaillard C, Bellon G, Vital Durand D. Magnetic resonance cholangiography in cystic fibrosis [Abstract]. Pediatr Pulmonol 1997;14(S):307
59. Wagner JA, Chao AC, Gardner P. Molecular strategies for therapy of cystic fibrosis. Annu Rev Pharmacol Toxicol 1995;35: 257-276
60. Delaney SJ, Wainwright BJ. New pharmaceutical approaches to the treatment of cystic fibrosis. Nature Medicine 1996;2:392-393
61. Yang Y, Raper SE, Cohn JA, Engelhardt JF, Wilson JM An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer Proc Natl Acad Sci USA 1993;90:4601-4605
62. Grubman SH, Fang SL, Mulberg AE, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 1995;108, 584-592
63. Rubin RA, Kowalski TE, Khandelwal M, Malet PF Ursodiol for hepatobiliary disorders. Ann Intern Med 1994;121:207-218
64. Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: The role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997;24:573-589
65. Noble-Jamieson G, Valente J, Barnes ND, et al. Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 1994;71:349-352
66. Poupon RE, Poupon R, Balkau B and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994,330:1342-1347
67. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 1993;104:1865-1870
68. Crosignani A, Setchell KDR, Invernizzi P, Larghi A, Rodrigues CMP, Podda M Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996;30:333-358
69. Beuers U, Kullak-Ublick GA, Paumgartner G. Mechanism of action of UDCA in cholestatic syndromes. In: Alvaro A, Benedetti B, Strazzabosco M (eds): Vanishing bile duct syndrome: Pathoogy and treatment. Dordrecht, Kluwer Academic Publishers. 1997, pp 230-239
70. Van Nieuwkerk C, de Vree M, Van Vijland M, et al. The role of mdr-2 P-glycoprotein in lipid secretion and ductular damage. In: Alvaro A, Benedetti B, Strazzabosco M (eds): Vanishing bile duct syndrome: Pathophysiology and treatment. Dordrecht. Kluwer Academic Publishers. 1997, pp 128-132
71. 2+ mechanisms defective in cholestasis J Clin Invest 1993;92:2984-2993
72. Strazzabosco M, Poci C, Spirl C, Knuth A, Sartori L, Crepaldi G. Effect of ursodeoxycholic acid (UDCA) on intracellular pH in a bile duct epithelium-like cell line. Hepatology 1994;19:145-154
73. Shimokura GH, McGill M, Fitz JG. Ursodeoxycholate activates ion permeabilities in biliary epithelial cells. Gastroenterology 1994;107:236-243
74. Colombo C, Crosignani A, Assaisso MI., et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study. Hepatology 1992;16:924-930
75. Colombo C, Castellani MR. Crosignani A, Comi S, Giunta A. Abnormalities in biliary drainage may predict a better response to ursodeoxycholic acid in cystic fibrosis-associated liver disease [Abstract]. Hepatology 1996;24:201A
76. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis. Hepatology. 1998;23:166-174.
77. Cotting J, Lentze M, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with fibrosis and long-standing cholestasis. 1990;Gut 31: 918-921
78. Lepage G, Paradis K. Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in chidren with cystic fibrosis. J Pediatr 1997;130:52-58
79. Dodge JA Custance JM, Goodchild MC, Laing SC, Vaughan M. Paradoxical effects of essential fatty acid supplementation on lipid profiles and sweat electrolytes in cystic fibrosis. Br J Nutr 1990;63.259-271
80. Bittner P, Posselt HG, Sailer T, et al. The effect of treatment with ursodeoxycholic acid in cystic fibrosis and hepatopathy: Results of a placebo-controlled study. In: Paumgartner G, Stiehl A, Gerok W (eds): Bile acids as therapeutic agents - from basic science to clinical practice. Dordrecht, Kluwer Academic Publishers, 1991, pp 345-348
81. O'Brien S, Fitzgerald MX, Hegarty JE. A controlled trial of ursodeoxycholic acid treatment in cystic fibrosis -related liver disease. Eur J Gastroenterol Hepatol. 1992;4:857-863
82. Merli M, Bertasi S, Servi R, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: A randomized, placebo-controlled, crossover trial. J Pediatr Gastroenterol Nutr 1994;19:198-203
83. Colombo C, Battezzati PM, Podda M, Bettinardi, Giunta A and the Italian Group for the Study of Ursodeoxycholic acid in Cystic Fibrosis. Ursodeoxycholic Acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial. Hepatology 1996;23:1484-1490
84. Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid in cystic fibrosis-related liver disease. J R Soc Med 1997;90 (S31):6-12